华法林药物基因组学和个体化用药  

Pharmacogenomics of warfarin and its personalized treatment

作　　者：彭娟[1] 谭胜蓝[1] 周宏灏[1] 李智[1] 

机构地区：[1]中南大学临床药理研究所,湖南长沙410078

出　　处：《中国药理学通报》2013年第2期169-172,共4页Chinese Pharmacological Bulletin

基　　金：国家高技术研究发展计划(863计划)(No2012AA02A518);湖南省高校创新平台开放基金(No11K073)

摘　　要：华法林是临床使用最广泛的口服抗凝药,其治疗窗窄,剂量个体差异大,容易发生出血或栓塞的风险。CYP2C9和VKORC1基因多态性明显影响华法林剂量。其他参与维生素摄入和循环,华法林转运的基因变异,以及microRNA也可能影响华法林剂量。该文结合国内外各种华法林稳定剂量预测模型研究,总结影响华法林剂量相关基因的最新研究进展,旨在为华法林个体化治疗提供参考和指导依据。Warfarin is the most widely used oral anticoagulant with narrow therapeutic window, wide inter-individual variability and high risks of bleeding or thromboembolism. Polymorphisms in CYP2C9 and VKORC1 are the major determinants of warfarin dosage requirement. Other genetic factors involving in vitamin K intake and recycle, and warfarin transportation may influence warfarin stable maintenance dosage as well. microRNA might also play a role. Based on numerous warfarin stable dosage prediction algorithms studies, this review updates the studies of warfarin pharmacogenomics and its personalized treatment, with the aim of providing evidence for clinical practice.

关 键 词：华法林 个体化治疗 基因多态性 剂量模型 VKORC1 CYP2C9 

分 类 号：R-05[医药卫生] R394.2